Prescient Therapeutics LimitedASX: PTX

Yale Joins PTXs Phase 1b/2 AML Clinical Trial

Jun 15, 2016 at 5:18 AM UTC · Issued by Prescient Therapeutics Limited

Prescient Therapeutics Ltd has released a press release.

View Attachment